Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 83

1.

Integrated Single-Cell Analysis Maps the Continuous Regulatory Landscape of Human Hematopoietic Differentiation.

Buenrostro JD, Corces MR, Lareau CA, Wu B, Schep AN, Aryee MJ, Majeti R, Chang HY, Greenleaf WJ.

Cell. 2018 May 31;173(6):1535-1548.e16. doi: 10.1016/j.cell.2018.03.074. Epub 2018 Apr 26.

PMID:
29706549
2.

Proposed Terminology and Classification of Pre-Malignant Neoplastic Conditions: A Consensus Proposal.

Valent P, Akin C, Arock M, Bock C, George TI, Galli SJ, Gotlib J, Haferlach T, Hoermann G, Hermine O, Jäger U, Kenner L, Kreipe H, Majeti R, Metcalfe DD, Orfao A, Reiter A, Sperr WR, Staber PB, Sotlar K, Schiffer C, Superti-Furga G, Horny HP.

EBioMedicine. 2017 Dec;26:17-24. doi: 10.1016/j.ebiom.2017.11.024. Epub 2017 Nov 26. Review.

3.

Single-cell analysis reveals the continuum of human lympho-myeloid progenitor cells.

Karamitros D, Stoilova B, Aboukhalil Z, Hamey F, Reinisch A, Samitsch M, Quek L, Otto G, Repapi E, Doondeea J, Usukhbayar B, Calvo J, Taylor S, Goardon N, Six E, Pflumio F, Porcher C, Majeti R, Göttgens B, Vyas P.

Nat Immunol. 2018 Jan;19(1):85-97. doi: 10.1038/s41590-017-0001-2. Epub 2017 Nov 21.

4.

Preleukemic Hematopoietic Stem Cells in Human Acute Myeloid Leukemia.

Corces MR, Chang HY, Majeti R.

Front Oncol. 2017 Nov 6;7:263. doi: 10.3389/fonc.2017.00263. eCollection 2017. Review.

5.

Multiplexed genetic engineering of human hematopoietic stem and progenitor cells using CRISPR/Cas9 and AAV6.

Bak RO, Dever DP, Reinisch A, Cruz Hernandez D, Majeti R, Porteus MH.

Elife. 2017 Sep 28;6. pii: e27873. doi: 10.7554/eLife.27873.

6.

Generation and use of a humanized bone-marrow-ossicle niche for hematopoietic xenotransplantation into mice.

Reinisch A, Hernandez DC, Schallmoser K, Majeti R.

Nat Protoc. 2017 Oct;12(10):2169-2188. doi: 10.1038/nprot.2017.088. Epub 2017 Sep 21.

7.

Superenhancer Analysis Defines Novel Epigenomic Subtypes of Non-APL AML, Including an RARα Dependency Targetable by SY-1425, a Potent and Selective RARα Agonist.

McKeown MR, Corces MR, Eaton ML, Fiore C, Lee E, Lopez JT, Chen MW, Smith D, Chan SM, Koenig JL, Austgen K, Guenther MG, Orlando DA, Lovén J, Fritz CC, Majeti R.

Cancer Discov. 2017 Oct;7(10):1136-1153. doi: 10.1158/2159-8290.CD-17-0399. Epub 2017 Jul 20.

8.

Systematic discovery of mutation-specific synthetic lethals by mining pan-cancer human primary tumor data.

Sinha S, Thomas D, Chan S, Gao Y, Brunen D, Torabi D, Reinisch A, Hernandez D, Chan A, Rankin EB, Bernards R, Majeti R, Dill DL.

Nat Commun. 2017 May 31;8:15580. doi: 10.1038/ncomms15580.

9.

Optimizing Next-Generation AML Therapy: Activity of Mutant IDH2 Inhibitor AG-221 in Preclinical Models.

Thomas D, Majeti R.

Cancer Discov. 2017 May;7(5):459-461. doi: 10.1158/2159-8290.CD-17-0270.

10.

Disrupting the CD47-SIRPα anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors.

Gholamin S, Mitra SS, Feroze AH, Liu J, Kahn SA, Zhang M, Esparza R, Richard C, Ramaswamy V, Remke M, Volkmer AK, Willingham S, Ponnuswami A, McCarty A, Lovelace P, Storm TA, Schubert S, Hutter G, Narayanan C, Chu P, Raabe EH, Harsh G 4th, Taylor MD, Monje M, Cho YJ, Majeti R, Volkmer JP, Fisher PG, Grant G, Steinberg GK, Vogel H, Edwards M, Weissman IL, Cheshier SH.

Sci Transl Med. 2017 Mar 15;9(381). pii: eaaf2968. doi: 10.1126/scitranslmed.aaf2968.

PMID:
28298418
11.

Biology and relevance of human acute myeloid leukemia stem cells.

Thomas D, Majeti R.

Blood. 2017 Mar 23;129(12):1577-1585. doi: 10.1182/blood-2016-10-696054. Epub 2017 Feb 3. Review.

12.

Human AML-iPSCs Reacquire Leukemic Properties after Differentiation and Model Clonal Variation of Disease.

Chao MP, Gentles AJ, Chatterjee S, Lan F, Reinisch A, Corces MR, Xavy S, Shen J, Haag D, Chanda S, Sinha R, Morganti RM, Nishimura T, Ameen M, Wu H, Wernig M, Wu JC, Majeti R.

Cell Stem Cell. 2017 Mar 2;20(3):329-344.e7. doi: 10.1016/j.stem.2016.11.018. Epub 2017 Jan 12.

13.

Sticking It to the Niche: CD98 Mediates Critical Adhesive Signals in AML.

Reinisch A, Majeti R.

Cancer Cell. 2016 Nov 14;30(5):662-664. doi: 10.1016/j.ccell.2016.10.014.

14.

CRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells.

Dever DP, Bak RO, Reinisch A, Camarena J, Washington G, Nicolas CE, Pavel-Dinu M, Saxena N, Wilkens AB, Mantri S, Uchida N, Hendel A, Narla A, Majeti R, Weinberg KI, Porteus MH.

Nature. 2016 Nov 17;539(7629):384-389. doi: 10.1038/nature20134. Epub 2016 Nov 7.

15.

Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypes.

Matre P, Velez J, Jacamo R, Qi Y, Su X, Cai T, Chan SM, Lodi A, Sweeney SR, Ma H, Davis RE, Baran N, Haferlach T, Su X, Flores ER, Gonzalez D, Konoplev S, Samudio I, DiNardo C, Majeti R, Schimmer AD, Li W, Wang T, Tiziani S, Konopleva M.

Oncotarget. 2016 Nov 29;7(48):79722-79735. doi: 10.18632/oncotarget.12944.

16.

The role of mutations in the cohesin complex in acute myeloid leukemia.

Mazumdar C, Majeti R.

Int J Hematol. 2017 Jan;105(1):31-36. doi: 10.1007/s12185-016-2119-7. Epub 2016 Oct 28. Review.

17.

Autophagy mediates proteolysis of NPM1 and HEXIM1 and sensitivity to BET inhibition in AML cells.

Huang M, Garcia JS, Thomas D, Zhu L, Nguyen LX, Chan SM, Majeti R, Medeiros BC, Mitchell BS.

Oncotarget. 2016 Nov 15;7(46):74917-74930. doi: 10.18632/oncotarget.12493.

18.

Lineage-specific and single-cell chromatin accessibility charts human hematopoiesis and leukemia evolution.

Corces MR, Buenrostro JD, Wu B, Greenside PG, Chan SM, Koenig JL, Snyder MP, Pritchard JK, Kundaje A, Greenleaf WJ, Majeti R, Chang HY.

Nat Genet. 2016 Oct;48(10):1193-203. doi: 10.1038/ng.3646. Epub 2016 Aug 15.

19.
20.

Burning Fat Fuels Leukemic Stem Cell Heterogeneity.

Thomas D, Majeti R.

Cell Stem Cell. 2016 Jul 7;19(1):1-2. doi: 10.1016/j.stem.2016.06.014.

21.

CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer.

Weiskopf K, Jahchan NS, Schnorr PJ, Cristea S, Ring AM, Maute RL, Volkmer AK, Volkmer JP, Liu J, Lim JS, Yang D, Seitz G, Nguyen T, Wu D, Jude K, Guerston H, Barkal A, Trapani F, George J, Poirier JT, Gardner EE, Miles LA, de Stanchina E, Lofgren SM, Vogel H, Winslow MM, Dive C, Thomas RK, Rudin CM, van de Rijn M, Majeti R, Garcia KC, Weissman IL, Sage J.

J Clin Invest. 2016 Jul 1;126(7):2610-20. doi: 10.1172/JCI81603. Epub 2016 Jun 13.

22.

A humanized bone marrow ossicle xenotransplantation model enables improved engraftment of healthy and leukemic human hematopoietic cells.

Reinisch A, Thomas D, Corces MR, Zhang X, Gratzinger D, Hong WJ, Schallmoser K, Strunk D, Majeti R.

Nat Med. 2016 Jul;22(7):812-21. doi: 10.1038/nm.4103. Epub 2016 May 23.

23.

ASH1L Links Histone H3 Lysine 36 Dimethylation to MLL Leukemia.

Zhu L, Li Q, Wong SH, Huang M, Klein BJ, Shen J, Ikenouye L, Onishi M, Schneidawind D, Buechele C, Hansen L, Duque-Afonso J, Zhu F, Martin GM, Gozani O, Majeti R, Kutateladze TG, Cleary ML.

Cancer Discov. 2016 Jul;6(7):770-83. doi: 10.1158/2159-8290.CD-16-0058. Epub 2016 May 6.

24.

SIRPα-Antibody Fusion Proteins Selectively Bind and Eliminate Dual Antigen-Expressing Tumor Cells.

Piccione EC, Juarez S, Tseng S, Liu J, Stafford M, Narayanan C, Wang L, Weiskopf K, Majeti R.

Clin Cancer Res. 2016 Oct 15;22(20):5109-5119. Epub 2016 Apr 28.

25.

Anti-CD47 Treatment Stimulates Phagocytosis of Glioblastoma by M1 and M2 Polarized Macrophages and Promotes M1 Polarized Macrophages In Vivo.

Zhang M, Hutter G, Kahn SA, Azad TD, Gholamin S, Xu CY, Liu J, Achrol AS, Richard C, Sommerkamp P, Schoen MK, McCracken MN, Majeti R, Weissman I, Mitra SS, Cheshier SH.

PLoS One. 2016 Apr 19;11(4):e0153550. doi: 10.1371/journal.pone.0153550. eCollection 2016.

26.

Leukemia-Associated Cohesin Mutants Dominantly Enforce Stem Cell Programs and Impair Human Hematopoietic Progenitor Differentiation.

Mazumdar C, Shen Y, Xavy S, Zhao F, Reinisch A, Li R, Corces MR, Flynn RA, Buenrostro JD, Chan SM, Thomas D, Koenig JL, Hong WJ, Chang HY, Majeti R.

Cell Stem Cell. 2015 Dec 3;17(6):675-688. doi: 10.1016/j.stem.2015.09.017. Epub 2015 Oct 22.

27.

Clonal evolution of preleukemic hematopoietic stem cells in acute myeloid leukemia.

Sykes SM, Kokkaliaris KD, Milsom MD, Levine RL, Majeti R.

Exp Hematol. 2015 Dec;43(12):989-92. doi: 10.1016/j.exphem.2015.08.012. Epub 2015 Oct 9. Review.

28.

An LSC epigenetic signature is largely mutation independent and implicates the HOXA cluster in AML pathogenesis.

Jung N, Dai B, Gentles AJ, Majeti R, Feinberg AP.

Nat Commun. 2015 Oct 7;6:8489. doi: 10.1038/ncomms9489.

29.

Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential.

Liu J, Wang L, Zhao F, Tseng S, Narayanan C, Shura L, Willingham S, Howard M, Prohaska S, Volkmer J, Chao M, Weissman IL, Majeti R.

PLoS One. 2015 Sep 21;10(9):e0137345. doi: 10.1371/journal.pone.0137345. eCollection 2015.

30.

Biology and Clinical Relevance of Acute Myeloid Leukemia Stem Cells.

Reinisch A, Chan SM, Thomas D, Majeti R.

Semin Hematol. 2015 Jul;52(3):150-64. doi: 10.1053/j.seminhematol.2015.03.008. Epub 2015 Mar 18. Review.

31.

A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells.

Piccione EC, Juarez S, Liu J, Tseng S, Ryan CE, Narayanan C, Wang L, Weiskopf K, Majeti R.

MAbs. 2015;7(5):946-56. doi: 10.1080/19420862.2015.1062192.

32.

Reply to Fišer et al.: Myeloid reprogramming of Ph+ B-ALL: A potential therapeutic strategy.

Majeti R, Dove C, McClellan JS.

Proc Natl Acad Sci U S A. 2015 Jul 7;112(27):E3456. doi: 10.1073/pnas.1509027112. Epub 2015 Jun 11. No abstract available.

33.

Reprogramming of primary human Philadelphia chromosome-positive B cell acute lymphoblastic leukemia cells into nonleukemic macrophages.

McClellan JS, Dove C, Gentles AJ, Ryan CE, Majeti R.

Proc Natl Acad Sci U S A. 2015 Mar 31;112(13):4074-9. doi: 10.1073/pnas.1413383112. Epub 2015 Mar 16.

34.

Tuning cytokine receptor signaling by re-orienting dimer geometry with surrogate ligands.

Moraga I, Wernig G, Wilmes S, Gryshkova V, Richter CP, Hong WJ, Sinha R, Guo F, Fabionar H, Wehrman TS, Krutzik P, Demharter S, Plo I, Weissman IL, Minary P, Majeti R, Constantinescu SN, Piehler J, Garcia KC.

Cell. 2015 Mar 12;160(6):1196-208. doi: 10.1016/j.cell.2015.02.011. Epub 2015 Feb 26.

35.

Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia.

Chan SM, Thomas D, Corces-Zimmerman MR, Xavy S, Rastogi S, Hong WJ, Zhao F, Medeiros BC, Tyvoll DA, Majeti R.

Nat Med. 2015 Feb;21(2):178-84. doi: 10.1038/nm.3788. Epub 2015 Jan 19.

36.

Clonal evolution of pre-leukemic hematopoietic stem cells precedes human acute myeloid leukemia.

Majeti R.

Best Pract Res Clin Haematol. 2014 Sep-Dec;27(3-4):229-34. doi: 10.1016/j.beha.2014.10.003. Epub 2014 Oct 15. Review.

37.

Epigenetic and in vivo comparison of diverse MSC sources reveals an endochondral signature for human hematopoietic niche formation.

Reinisch A, Etchart N, Thomas D, Hofmann NA, Fruehwirth M, Sinha S, Chan CK, Senarath-Yapa K, Seo EY, Wearda T, Hartwig UF, Beham-Schmid C, Trajanoski S, Lin Q, Wagner W, Dullin C, Alves F, Andreeff M, Weissman IL, Longaker MT, Schallmoser K, Majeti R, Strunk D.

Blood. 2015 Jan 8;125(2):249-60. doi: 10.1182/blood-2014-04-572255. Epub 2014 Nov 18.

38.

Mutant WT1 is associated with DNA hypermethylation of PRC2 targets in AML and responds to EZH2 inhibition.

Sinha S, Thomas D, Yu L, Gentles AJ, Jung N, Corces-Zimmerman MR, Chan SM, Reinisch A, Feinberg AP, Dill DL, Majeti R.

Blood. 2015 Jan 8;125(2):316-26. doi: 10.1182/blood-2014-03-566018. Epub 2014 Nov 14.

39.

Pre-leukemic evolution of hematopoietic stem cells: the importance of early mutations in leukemogenesis.

Corces-Zimmerman MR, Majeti R.

Leukemia. 2014 Dec;28(12):2276-82. doi: 10.1038/leu.2014.211. Epub 2014 Jul 9. Review.

40.

Refractory warm IgM-mediated autoimmune hemolytic anemia associated with Churg-Strauss syndrome responsive to eculizumab and rituximab.

Chao MP, Hong J, Kunder C, Lester L, Schrier SL, Majeti R.

Am J Hematol. 2015 Jan;90(1):78-81. doi: 10.1002/ajh.23791. Epub 2014 Jul 11. No abstract available.

41.

Transient expression of Bcl6 is sufficient for oncogenic function and induction of mature B-cell lymphoma.

Green MR, Vicente-Dueñas C, Romero-Camarero I, Long Liu C, Dai B, González-Herrero I, García-Ramírez I, Alonso-Escudero E, Iqbal J, Chan WC, Campos-Sanchez E, Orfao A, Pintado B, Flores T, Blanco O, Jiménez R, Martínez-Climent JA, Criado FJ, Cenador MB, Zhao S, Natkunam Y, Lossos IS, Majeti R, Melnick A, Cobaleda C, Alizadeh AA, Sánchez-García I.

Nat Commun. 2014 Jun 2;5:3904. doi: 10.1038/ncomms4904.

42.

Interaction of TIF-90 and filamin A in the regulation of rRNA synthesis in leukemic cells.

Nguyen le XT, Chan SM, Ngo TD, Raval A, Kim KK, Majeti R, Mitchell BS.

Blood. 2014 Jul 24;124(4):579-89. doi: 10.1182/blood-2013-12-544726. Epub 2014 May 21.

43.

Centrosome-kinase fusions promote oncogenic signaling and disrupt centrosome function in myeloproliferative neoplasms.

Lee JY, Hong WJ, Majeti R, Stearns T.

PLoS One. 2014 Mar 21;9(3):e92641. doi: 10.1371/journal.pone.0092641. eCollection 2014.

44.

Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission.

Corces-Zimmerman MR, Hong WJ, Weissman IL, Medeiros BC, Majeti R.

Proc Natl Acad Sci U S A. 2014 Feb 18;111(7):2548-53. doi: 10.1073/pnas.1324297111. Epub 2014 Feb 3.

45.

Role of DNMT3A, TET2, and IDH1/2 mutations in pre-leukemic stem cells in acute myeloid leukemia.

Chan SM, Majeti R.

Int J Hematol. 2013 Dec;98(6):648-57. doi: 10.1007/s12185-013-1407-8. Epub 2013 Aug 15. Review.

46.

Role of cysteine 288 in nucleophosmin cytoplasmic mutations: sensitization to toxicity induced by arsenic trioxide and bortezomib.

Huang M, Thomas D, Li MX, Feng W, Chan SM, Majeti R, Mitchell BS.

Leukemia. 2013 Oct;27(10):1970-80. doi: 10.1038/leu.2013.222. Epub 2013 Jul 23.

PMID:
23877794
47.

The cancer stem cell model: B cell acute lymphoblastic leukaemia breaks the mould.

McClellan JS, Majeti R.

EMBO Mol Med. 2013 Jan;5(1):7-9. doi: 10.1002/emmm.201202207. Epub 2012 Dec 11. No abstract available.

48.

Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia.

Craddock C, Quek L, Goardon N, Freeman S, Siddique S, Raghavan M, Aztberger A, Schuh A, Grimwade D, Ivey A, Virgo P, Hills R, McSkeane T, Arrazi J, Knapper S, Brookes C, Davies B, Price A, Wall K, Griffiths M, Cavenagh J, Majeti R, Weissman I, Burnett A, Vyas P.

Leukemia. 2013 Apr;27(5):1028-36. doi: 10.1038/leu.2012.312. Epub 2012 Nov 6.

PMID:
23223186
49.

Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia.

Jan M, Snyder TM, Corces-Zimmerman MR, Vyas P, Weissman IL, Quake SR, Majeti R.

Sci Transl Med. 2012 Aug 29;4(149):149ra118. doi: 10.1126/scitranslmed.3004315.

50.

Cyclin-A1 represents a new immunogenic targetable antigen expressed in acute myeloid leukemia stem cells with characteristics of a cancer-testis antigen.

Ochsenreither S, Majeti R, Schmitt T, Stirewalt D, Keilholz U, Loeb KR, Wood B, Choi YE, Bleakley M, Warren EH, Hudecek M, Akatsuka Y, Weissman IL, Greenberg PD.

Blood. 2012 Jun 7;119(23):5492-501. doi: 10.1182/blood-2011-07-365890. Epub 2012 Apr 23.

Supplemental Content

Loading ...
Support Center